CO6270332A2 - Compuesto de alfa-(n-sulfonamido)acetamida novedoso como inhibidor de produccion de peptido beta amiloide - Google Patents

Compuesto de alfa-(n-sulfonamido)acetamida novedoso como inhibidor de produccion de peptido beta amiloide

Info

Publication number
CO6270332A2
CO6270332A2 CO10049723A CO10049723A CO6270332A2 CO 6270332 A2 CO6270332 A2 CO 6270332A2 CO 10049723 A CO10049723 A CO 10049723A CO 10049723 A CO10049723 A CO 10049723A CO 6270332 A2 CO6270332 A2 CO 6270332A2
Authority
CO
Colombia
Prior art keywords
acetamide
novedous
alfa
sulfonamide
compound
Prior art date
Application number
CO10049723A
Other languages
English (en)
Spanish (es)
Inventor
John E Starrett Jr
Kevin W Gillman
Richard Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6270332(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO6270332A2 publication Critical patent/CO6270332A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO10049723A 2007-10-31 2010-04-27 Compuesto de alfa-(n-sulfonamido)acetamida novedoso como inhibidor de produccion de peptido beta amiloide CO6270332A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31

Publications (1)

Publication Number Publication Date
CO6270332A2 true CO6270332A2 (es) 2011-04-20

Family

ID=40193955

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10049723A CO6270332A2 (es) 2007-10-31 2010-04-27 Compuesto de alfa-(n-sulfonamido)acetamida novedoso como inhibidor de produccion de peptido beta amiloide

Country Status (28)

Country Link
US (2) US8084477B2 (https=)
EP (3) EP2205575B1 (https=)
JP (1) JP5460605B2 (https=)
KR (1) KR20100075575A (https=)
CN (2) CN101910141B (https=)
AR (1) AR069135A1 (https=)
AT (1) ATE502022T1 (https=)
AU (1) AU2008319122A1 (https=)
BR (1) BRPI0818837A2 (https=)
CA (1) CA2704360A1 (https=)
CL (1) CL2008003271A1 (https=)
CO (1) CO6270332A2 (https=)
CY (2) CY1112337T1 (https=)
DE (1) DE602008005636D1 (https=)
DK (2) DK2205575T3 (https=)
EA (2) EA201171439A1 (https=)
ES (2) ES2390042T3 (https=)
HR (2) HRP20110219T1 (https=)
IL (1) IL205406A0 (https=)
MX (1) MX2010004319A (https=)
NZ (1) NZ584545A (https=)
PE (1) PE20091394A1 (https=)
PL (2) PL2205575T3 (https=)
PT (2) PT2295417E (https=)
SG (2) SG174044A1 (https=)
SI (2) SI2295417T1 (https=)
TW (1) TW200927099A (https=)
WO (1) WO2009058552A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α-(N-磺酰氨基)乙酰胺衍生物作为β-淀粉样蛋白抑制剂
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
JP2012520875A (ja) * 2009-03-19 2012-09-10 ブリストル−マイヤーズ スクイブ カンパニー ベータアミロイドペプチド産生阻害剤としての新規アルファ−(n−スルホンアミド)アセトアミド化合物
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
BR122017023123B1 (pt) 2010-03-12 2018-04-24 Nippon Soda Co., Ltd. Método para produzir derivado de picolina halogenada
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
EP2643299B1 (en) 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
MX390370B (es) 2016-12-16 2025-03-20 Pipeline Therapeutics Inc Metodos para tratar la sinaptopatia coclear
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
KR20220024729A (ko) 2019-06-24 2022-03-03 노파르티스 아게 B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
IL123901A (en) 1995-11-17 2003-06-24 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases and pharmaceutical compositions comprising them
EP0939629A4 (en) 1996-07-22 2002-07-17 Monsanto Co THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するTNF―α産生抑制剤
IL144347A0 (en) 1999-01-27 2002-05-23 American Cyanamid Co Acetylenic sulfonamide thiol tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
WO2000050391A1 (en) * 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
IL159140A0 (en) * 2001-12-14 2004-06-01 Raytheon Co Precisely aligned lens structure and a method for its fabrication
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α-(N-磺酰氨基)乙酰胺衍生物作为β-淀粉样蛋白抑制剂
IL163643A0 (en) * 2002-02-28 2005-12-18 Astrazeneca Ab Oxazolidinone derivatives, processes for their forpreparation, and pharmaceutical compositions containing them
EP1460070B1 (en) * 2003-03-20 2007-05-16 Santhera Pharmaceuticals (Schweiz) AG Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
BRPI0408962A (pt) 2003-03-31 2006-04-04 Wyeth Corp inibidores sulfonamidas heterocìclicos contendo flúor- e trifluoroalquila da produção de beta amilóide e seus derivados
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
PE20080169A1 (es) 2006-02-17 2008-04-11 Wyeth Corp Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
US7838550B2 (en) 2006-02-17 2010-11-23 Wyeth Llc Selective N-sulfonylation of 2-amino fluoro- and trifluoroalkyl substituted alcohols
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
HK1141801A1 (en) 2010-11-19
HRP20110219T1 (hr) 2011-04-30
AU2008319122A1 (en) 2009-05-07
PE20091394A1 (es) 2009-09-25
JP2011502153A (ja) 2011-01-20
PL2205575T3 (pl) 2011-09-30
EP2295417B1 (en) 2012-07-04
DK2205575T3 (da) 2011-07-11
IL205406A0 (en) 2010-12-30
DK2295417T3 (da) 2012-10-15
CY1112337T1 (el) 2015-12-09
PT2205575E (pt) 2011-05-23
CN102718689A (zh) 2012-10-10
CN101910141B (zh) 2012-12-19
SG174044A1 (en) 2011-09-29
EP2295417A1 (en) 2011-03-16
US20090111858A1 (en) 2009-04-30
BRPI0818837A2 (pt) 2015-04-22
US20120088925A1 (en) 2012-04-12
ES2390042T3 (es) 2012-11-06
EA201171439A1 (ru) 2012-05-30
DE602008005636D1 (de) 2011-04-28
CL2008003271A1 (es) 2009-07-10
HRP20120703T1 (hr) 2012-09-30
US8084477B2 (en) 2011-12-27
PL2295417T3 (pl) 2012-11-30
NZ584545A (en) 2011-04-29
EA016447B1 (ru) 2012-05-30
ATE502022T1 (de) 2011-04-15
HK1155161A1 (en) 2012-05-11
SG174043A1 (en) 2011-09-29
ES2361283T3 (es) 2011-06-15
US8350084B2 (en) 2013-01-08
MX2010004319A (es) 2010-04-30
AR069135A1 (es) 2009-12-30
CA2704360A1 (en) 2009-05-07
EP2205575B1 (en) 2011-03-16
TW200927099A (en) 2009-07-01
EA201000714A1 (ru) 2010-10-29
EP2205575A1 (en) 2010-07-14
EP2471769A1 (en) 2012-07-04
CY1113346T1 (el) 2016-06-22
CN101910141A (zh) 2010-12-08
SI2295417T1 (sl) 2012-11-30
PT2295417E (pt) 2012-09-26
KR20100075575A (ko) 2010-07-02
JP5460605B2 (ja) 2014-04-02
SI2205575T1 (sl) 2011-07-29
WO2009058552A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CO6270332A2 (es) Compuesto de alfa-(n-sulfonamido)acetamida novedoso como inhibidor de produccion de peptido beta amiloide
CL2008001960A1 (es) Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
CL2007001030A1 (es) Compuestos derivados de heterociclilguanidina; y composicion farmaceutica, util para el tratamiento de la enfermedad de alzheimer, demencia senil y demencia asociada a enfermedad de parkinson entre otras.
EA201291413A1 (ru) Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
CL2007002427A1 (es) Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes.
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ECSP088876A (es) Formas de polimorfos de la (2s)-(4e)-n-metil-5-(3-isopropoxipiridin)il]-4-penten-2-amina para el tratamiento de desórdenes del sistema nervioso central
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
CL2007002288A1 (es) Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro
CL2007003423A1 (es) Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
GT201000045A (es) Derivados de ciclopropilamida '978
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
CL2007002479A1 (es) Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos.
NI200900207A (es) Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas.
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.
CR7876A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed